Stock SBFM SUNSHINE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sunshine Biopharma, Inc.

Equities

SBFM

US8677816014

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 12:35:05 29/04/2024 BST 		5-day change 1st Jan Change
0.97 USD +2.11% Intraday chart for Sunshine Biopharma, Inc. -46.18% -96.50%
04-19 Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product MT
04-19 Top Premarket Decliners MT

Business Summary

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Number of employees: 44

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
4 100.0 % 24 100.0 % +454.42%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
4 100.0 % 24 100.0 % +454.42%

Managers

Managers TitleAgeSince
Steve Slilaty CEO
 Chief Executive Officer 71 14/10/09
Camille Sebaaly DFI
 Director of Finance/CFO 62 14/10/09
Marc Beaudoin COO
 Chief Operating Officer - 01-24
Abderrazzak Merzouki CTO
 Chief Tech/Sci/R&D Officer 60 31/01/16
Malek Chamoun PRN
 Corporate Officer/Principal 39 01-24

Members of the board

Members of the board TitleAgeSince
David Natan BRD
 Director/Board Member 70 31/01/22
Steve Slilaty CEO
 Chief Executive Officer 71 14/10/09
Camille Sebaaly DFI
 Director of Finance/CFO 62 14/10/09
Abderrazzak Merzouki CTO
 Chief Tech/Sci/R&D Officer 60 31/01/16
Rabi Kiderchah BRD
 Director/Board Member 51 30/10/21
Andrew Keller BRD
 Director/Board Member 70 09/02/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 994,529 900,534 ( 90.55 %) 0 90.55 %
Stock B 0 10,000 0 0

Shareholders

NameEquities%Valuation
L1 Capital Global, Inc.
5.315 %
5,285,714 5.315 % 317 143 $
Altium Capital Management LP
3.748 %
3,727,984 3.748 % 223 679 $
Malek Chamoun
3.720 %
3,700,000 3.720 % 222 000 $
Armistice Capital LLC
2.142 %
2,130,000 2.142 % 127 800 $
Bridgeway Capital Management LLC
0.2877 %
286,100 0.2877 % 17 166 $
Camille Sebaaly
0.1754 %
174,465 0.1754 % 10 468 $
Steve Slilaty
0.1217 %
121,024 0.1217 % 7 261 $
Abderrazzak Merzouki
0.1174 %
116,720 0.1174 % 7 003 $
Renaissance Technologies LLC
0.0670 %
66,600 0.0670 % 3 996 $
Virtu Financial LLC
0.0240 %
23,862 0.0240 % 1 432 $
NameEquities%Valuation
Steve Slilaty
13.00 %
130,000 13.00 % 7 800 $
NameEquities%Valuation
Citadel Securities GP LLC
-
246,885 - 11 850 $
BofA Securities, Inc.
-
10,200 - 490 $
UBS Securities LLC
-
2,300 - 110 $
Clear Street LLC
-
2,076 - 100 $

Company contact information

Sunshine Biopharma, Inc.

1177 Avenue of the Americas 5th Floor

10036, New York

+

http://www.sunshinebiopharma.com
address Sunshine Biopharma, Inc.(SBFM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Sunshine Biopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.95 USD
Average target price
15 USD
Spread / Average Target
+1,478.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SUNSHINE BIOPHARMA, INC. Stock Sunshine Biopharma, Inc.
-96.50% 945K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.01% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.64% 231B
NOVARTIS AG Stock Novartis AG
+5.34% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.00% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SBFM Stock
  4. Company Sunshine Biopharma, Inc.